Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAR-210
- Development stage
- Phase 3
- Lead developer
- Janssen Research & Development
- Modality
- Small Molecules
- Administration
- Intravesical
01
Overview
TAR-210 (Erda-iDRS) is an investigational intravesical drug delivery system designed for the sustained local release of erdafitinib within the bladder. Erdafitinib is a potent tyrosine kinase inhibitor that targets the fibroblast growth factor receptors FGFR1, FGFR2, FGFR3, and FGFR4. The system consists of a drug-filled silicone tube that is inserted into the bladder via a catheter, where it continuously releases the medication to treat urothelial carcinoma, particularly in patients with FGFR alterations. This localized delivery approach is intended to maximize therapeutic concentrations at the tumor site while reducing systemic exposure and the associated side effects typically seen with oral FGFR inhibitors. TAR-210 is currently being developed by Janssen for the treatment of non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC).
- Other names
- Erdafitinib Intravesical Drug Delivery SystemErdafitinib iDRS
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on TAR-210.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAR-210.